1. Home
  2. TCRT vs APM Comparison

TCRT vs APM Comparison

Compare TCRT & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$3.27

Market Cap

7.7M

Sector

Health Care

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.78

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCRT
APM
Founded
1998
2010
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.0M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
TCRT
APM
Price
$3.27
$0.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.8K
15.7K
Earning Date
03-06-2026
10-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,900,000.00
N/A
Revenue This Year
$5,680,500.00
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.65
52 Week High
$5.48
$4.47

Technical Indicators

Market Signals
Indicator
TCRT
APM
Relative Strength Index (RSI) 51.84 41.98
Support Level $2.89 $0.74
Resistance Level $3.73 $0.86
Average True Range (ATR) 0.26 0.04
MACD -0.03 0.01
Stochastic Oscillator 30.56 26.07

Price Performance

Historical Comparison
TCRT
APM

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Share on Social Networks: